Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Twist Bioscience Corporation (TWST) Misses Q4 EPS by 5c
November 22, 2021 7:34 AM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($0.84), $0.05 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $38 million versus the consensus estimate of $37.02 million.
GUIDANCE:
Twist Bioscience Corporation sees FY2022 revenue of $183-193 million, versus the... More
